Basel Medical (BMGL) Fundamental Analysis: Revenue, Earnings & Valuation

0.91 / 10

Underperform

Fundamental rating is Underperform with a 0/10 quality score. EPS growth, diluted EPS, cash flow and profit YoY rates are deeply negative, placing all metrics in the lowest quartile. The company’s financial health appears severely deteriorated.

Analysis Checks(0/5)

Net cash flow from operating activities per share (YoY growth rate %)

Value-29.92

Score0/3

Weight23.70%

1M Return-3.08%

Basic earnings per share (YoY growth rate %)

Value-538.46

Score0/3

Weight14.31%

1M Return-1.82%

Total profit (YoY growth rate %)

Value-559.69

Score0/3

Weight25.06%

1M Return-3.20%

Net cash flow from operating activities (YoY growth rate %)

Value-261.16

Score0/3

Weight23.18%

1M Return-2.92%

Diluted earnings per share (YoY growth rate %)

Value-538.46

Score0/3

Weight13.74%

1M Return-1.72%

Is BMGL undervalued or overvalued?

BMGL scores 0.91/10 on fundamentals and holds a Premium valuation at present. Backed by its -163.63% ROE, -93.96% net margin, -1.33 P/E ratio, 2.59 P/B ratio, and -567.18% earnings growth, these metrics solidify its Underperform investment rating.